ORM1, also known as orosomucoid 1 or alpha-1 acid glycoprotein (AGP), is an acute-phase protein mainly synthesized in the liver. It constitutes a major part of serum ORM. As a plasma drug-binding protein, it can bind and carry numerous basic and neutral lipophilic drugs, and its genetic polymorphism may influence the binding ability and effect of drugs [3,4].

In the context of tuberculosis, in Mycobacterium tuberculosis (Mtb) antigen-stimulated peripheral blood mononuclear cells (PBMCs), ORM1 shows a high area under the curve (AUC) value in discriminating patients with active TB from those with latent TB infection, suggesting it could be a potential biomarker for this discrimination [1]. Regarding venous thromboembolism (VTE), a multiallelic copy number variation (mCNV) in ORM1 is associated with plasma cell-free DNA (cfDNA) levels, which could contribute to VTE risk. Increased mCNV dosages in ORM1 decrease gene expression and upregulate cfDNA levels [2,5].

In conclusion, ORM1 is a significant protein involved in drug-binding and potentially in disease diagnosis. Its role as a biomarker in tuberculosis and its association with VTE risk through cfDNA levels regulation are important findings. These insights from studies contribute to understanding its functions in disease-related biological processes, providing potential directions for diagnosis and treatment in these disease areas.